55
Participants
Start Date
June 8, 2020
Primary Completion Date
July 23, 2023
Study Completion Date
July 23, 2023
CB-5339
25mg and 75mg capsules
St. Vincent Hospital, Sydney, NSW, Darlinghurst
Epworth Healthcare, Melbourne
Haematology Clinical Trials Unit, Royal Perth Hospital, Perth
Memorial Sloan Kettering Cancer Center, New York
Weill Cornel Medical Center, New York
Saint Francis Hospital Cancer Center, Greenville
Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland
KU Clinical Research Center, Fairway
MD Anderson Cancer Cancer, Houston
USC Norris Comprehensive Cancer Center, Los Angeles
Lead Sponsor
Cleave Therapeutics, Inc.
INDUSTRY